Human EGFR-T790M/C797S Stable Cell Line-Ba/F3

The emergence of acquired resistance in cancers is a significant challenge, particularly concerning epidermal growth factor receptor (EGFR) mutations such as T790M and C797S. These mutations can hinder the efficacy of conventional EGFR-targeted therapies, leading to treatment failure. Researchers are actively exploring novel therapeutic strategies to overcome such resistance mechanisms. In this context, studies have shown that new derivatives of existing compounds, like lamellarin 14, can effectively target resistant mutant forms of EGFR. Specifically, Ba/F3 cells expressing the T790M/C797S double mutant have demonstrated sensitivity to lamellarin 14, suggesting its potential as a viable treatment option. This highlights the importance of developing stable cell lines that mimic resistant phenotypes for research and drug development purposes.

Figure 1. The researchers employed MTT assays to assess the viability of Ba/F3 cells expressing either wild-type or mutant EGFRs, treated with Lam14 or osimertinib, under varying conditions of interleukin-3. (Nishiya N, et al., 2021)

Creative Biogene's Human EGFR-T790M/C797S Stable Cell Line, derived from Ba/F3 cells, is designed for researchers investigating therapies against EGFR mutations. This cell line provides a reliable platform for evaluating the efficacy of new inhibitors, understanding resistance mechanisms, and screening potential drug candidates.